Found: 17
Select item for more details and to access through your institution.
Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 94, n. 2, p. 271, doi. 10.1007/s00280-024-04675-3
- By:
- Publication type:
- Article
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).
- Published in:
- Breast Cancer Research & Treatment, 2023, v. 198, n. 3, p. 487, doi. 10.1007/s10549-023-06889-0
- By:
- Publication type:
- Article
Quantitation of the ataxia‐telangiectasia‐mutated and Rad3‐related inhibitor elimusertib (BAY‐1895344) in human plasma using LC–MS/MS.
- Published in:
- Biomedical Chromatography, 2022, v. 36, n. 11, p. 1, doi. 10.1002/bmc.5455
- By:
- Publication type:
- Article
Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation.
- Published in:
- Scientific Reports, 2017, p. 41892, doi. 10.1038/srep41892
- By:
- Publication type:
- Article
ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.
- Published in:
- British Journal of Clinical Pharmacology, 2015, v. 80, n. 5, p. 1097, doi. 10.1111/bcp.12723
- By:
- Publication type:
- Article
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.
- Published in:
- British Journal of Clinical Pharmacology, 2019, v. 85, n. 11, p. 2499, doi. 10.1111/bcp.14054
- By:
- Publication type:
- Article
Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 6, p. 795, doi. 10.1007/s00280-022-04436-0
- By:
- Publication type:
- Article
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 5, p. 721, doi. 10.1007/s00280-022-04430-6
- By:
- Publication type:
- Article
Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 2, p. 231, doi. 10.1007/s00280-021-04388-x
- By:
- Publication type:
- Article
A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 49, doi. 10.1007/s00280-021-04350-x
- By:
- Publication type:
- Article
In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2020, v. 86, n. 5, p. 633, doi. 10.1007/s00280-020-04154-5
- By:
- Publication type:
- Article
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 8, p. 977, doi. 10.1002/jcph.892
- By:
- Publication type:
- Article